CLDN17

Across TCGA pan-cancer cohorts, CLDN17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN17 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CLDN17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLDN17 expression acts as an unfavorable survival marker.

LUSC, BRCA, and SKCM are the cancer types where CLDN17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
BRCA	OS	Median	All	0.410	0.924	.017	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLDN17–LUSC (DFS)

Open the LUSC breakdown →